Biorestorative Therapies (BRTX) Stock News

BioRestorative Therapies (NASDAQ:BRTX) has appointed Sandy Lipkins as a key executive focused on technology commercialization and business development, effective June 9, 2025. Lipkins brings over 30 years of venture capital, finance, and sales experience, with particular expertise in anti-aging and wellness sectors. His responsibilities will include managing strategic alliances and licensing agreements both domestically and internationally. Lipkins has a strong track record in stem cells, regenerative medicine, and tissue banking, along with experience in scaling companies and biologics manufacturing. CEO Lance Alstodt emphasized how Lipkins' expertise aligns with BRTX's mission to advance their clinical pipeline and expand their BioCosmeceuticals platform. The appointment represents a strategic move to accelerate growth and expand market presence in regenerative medicine.

BioRestorative Therapies (NASDAQ: BRTX) announced it will present new preliminary Phase 2 clinical data for BRTX-100, its stem cell therapy for chronic lumbar disc disease, at ISSCR 2025 in Hong Kong. The presentation will reveal blinded safety and efficacy data from 30 patients on June 13, 2025. BRTX-100, the company's lead candidate, is an autologous mesenchymal stem cell therapy targeting areas with limited blood flow. The Phase 2 trial is a randomized, double-blinded, placebo-controlled study across 16 U.S. sites, enrolling 99 patients in a 2:1 ratio of treatment to placebo. CEO Lance Alstodt highlighted strong signals in both safety and functional improvement. The company will release detailed data via press release before market open on June 13th.

BioRestorative Therapies (NASDAQ:BRTX) has reported its Q1 2025 financial results and provided significant clinical updates. The company's BRTX-100 program achieved major milestones, including FDA Fast Track designation for chronic lumbar disc disease (cLDD) treatment and IND clearance for chronic cervical discogenic pain. Preliminary clinical data from the Phase 2 trial showed positive safety profiles and efficacy trends. Financial results showed revenues of $25,000 (down from $35,000 in Q1 2024), with a net loss of $5.3 million ($0.64 per share). The company maintains a strong financial position with $9.1 million in cash and equivalents, with no outstanding debt. In their metabolic program, BioRestorative received a European patent allowance for their ThermoStem® platform and continues discussions regarding potential licensing agreements.

BioRestorative Therapies (NASDAQ:BRTX) has reported encouraging preliminary data from its Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD). The data, presented at the ISCT 2025 Annual Meeting, shows no serious adverse events (SAEs) and no dose-limiting toxicity at 26-104 weeks with 40X106 cells. The trial is demonstrating positive efficacy trends, exceeding the FDA's requirement of >30% improvement in both Oswestry Disability Index (ODI) and Visual Analog Scale (VAS). Notably, the percentage of subjects achieving >50% improvement in both ODI and VAS increased significantly from 0% at week 2 to 70% at week 52, maintaining at 66.66% through week 104, indicating strong and sustained therapeutic effects.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced it will release its Q1 2025 financial results on Wednesday, May 14, 2025, after market close.

The company will host a conference call at 4:30 p.m. ET to discuss the financial results and provide a business update. Investors can join via domestic (1-888-506-0062) or international (1-973-528-0011) lines using access code 924151. The call will be broadcast live and archived on the company's website in the Investors section.

BioRestorative Therapies (NASDAQ:BRTX) has announced that its Vice President of Research and Development, Francisco Silva, will present an update on the company's ongoing Phase 2 clinical trial of BRTX-100 for chronic lumbar disc disease (cLDD) at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting. The presentation, titled "Phase 2 Clinical Safety/Efficacy Data of Intradiscal Injection of Hypoxic Mesenchymal Stem Cells for Lumbar Disc Disease," will take place on Thursday, May 8, from 3:45-4:45 pm CT at the conference in New Orleans, LA.

BioRestorative Therapies (NASDAQ:BRTX), a clinical stage regenerative medicine company specializing in stem cell-based therapies, has announced its CEO Lance Alstodt will participate in the Benzinga All-Access Show on April 15, 2025, at 10:50 a.m. Eastern time.

During the interview, the company plans to discuss their recent achievements in clinical and regulatory milestones, along with highlighting commercial opportunities. The session will be accessible via live webcast and will subsequently be archived in the Investors section of the company's website.

BioRestorative Therapies (NASDAQ:BRTX) confirms no material impact from new U.S. tariffs due to its domestic production strategy for BRTX-100, its lead cell-based therapeutic targeting areas with blood flow. The company reports significant clinical progress with:

• FDA Fast Track designation for BRTX-100 in treating chronic lumbar disc disease (cLDD), following positive Phase 2 preliminary data
• FDA clearance of IND application for BRTX-100 in treating chronic cervical discogenic pain (cCDP)
• Strong financial position with over $10 million in cash, cash equivalents, and marketable securities at the end of 2024

BioRestorative Therapies (NASDAQ:BRTX) reported significant financial improvements for 2024, with total revenue increasing 175% to $401,000 from $146,000 in 2023. The company reduced its operating loss by 24% to $11.6 million and improved net loss by 14% to $9.0 million ($1.16 per share).

Key developments include:

• FDA Fast Track designation for BRTX-100 program for chronic lumbar disc disease (cLDD) treatment
• FDA clearance for BRTX-100 IND application for chronic cervical discogenic pain
• Provisional license from NY State Department of Health for allogeneic tissue processing
• Positive preliminary Phase 2 trial data for BRTX-100 showing no serious adverse events

The company ended 2024 with $10.7 million in cash and investments, with no outstanding debt. BioCosmeceuticals generated $300,000 in revenue for 2024.